ST. LOUIS, May 27, 2015 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, June 10, 2015, at the Goldman Sachs 36th Annual Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, Calif. The conference is June 9-11, 2015.
Mark Trudeau, President and Chief Executive Officer, and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a session scheduled to begin at 5:40 p.m. Eastern / 2:40 p.m. Pacific.
Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Vice President, Investor Relations
Senior Vice President, Communications and Public Affairs
SOURCE Mallinckrodt Pharmaceuticals